Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2025-12-25 @ 12:44 AM
NCT ID:
NCT04583267
Brief Summary:
The primary objective of this study is to examine acceptability, patterns of use, rates of adherence, safety , and measured levels of drug when high risk men who have sex with men (MSM) are provided open-label tenofovir/emtricitabine (TDF/FTC) for PrEP in South Korea. Secondary objectives are 1) to evaluate HIV incidence among study participants, 2) to evaluate risk behavior and risk compensation among study participants, and 3) to identify barriers and facilitators of PrEP among study participants. The design of this study is a prospective, open-label cohort study assessing PrEP implementation in tertiary hospital infectious diseases clinics in South Korea for 1 year. Baseline data will be collected 1 months before initiation of PrEP, and the date of initiation of PrEP. All persons receiving PrEP should be seen at 1 month since PrEP initiation and at least every 3 months to assess side effects, adherence, and HIV acquisition risk behaviors. Drug concentration will be measured every 6 months. It is anticipated that approximately 100 Korean MSM will be enrolled in this study.
Detailed Description:
1. Primary Objectives
• To examine acceptability, patterns of use, rates of adherence, safety , and measured levels of drug when high risk MSM are provided open-label TDF/FTC for PrEP in South Korea
2. Secondary Objectives
* To evaluate HIV incidence among study participants
* To evaluate risk behavior and risk compensation among study participants
* To identify barriers and facilitators of PrEP among study participants
3. Study design Prospective, open-label cohort study assessing PrEP delivery in tertiary hospital infectious diseases clinics in South Korea for 1 year
4. Evaluation
* Baseline evaluation
1. HIV testing and the documentation of results are required to confirm that patients do not have HIV infection when they start taking PrEP medications. HIV Ag/anti HIV Ab combo assay should be performed before starting PrEP. Negative result of HIV Ag/anti HIV Ab combo assay within 1 week should be ascertained before PrEP initiation. Results from rapid test with oral specimen or unreliable testing results cannot be acknowledged.
2. Renal function with estimated creatinine clearance (eCrCl) should be evaluated before starting TDF/FTC. TDF/FTC can be prescribed for persons with eCrCl ≥60 ml/min. Any person with an eCrCl of \<60 ml/min should not be prescribed PrEP with TDF/FTC.
3. Testing for hepatitis B virus (HBsAg, HBsAb) and hepatitis C virus (HCV Ab) should be performed before starting PrEP. Hepatitis B virus vaccination is recommended for MSM without HBsAb.
4. Acute HIV infection must be excluded by symptom history, physical examinations and appropriate HIV testing before PrEP is prescribed.
5. If HIV testing shows intermediate results, clinician should hold PrEP initiation, make efforts to identify symptoms and signs of acute viral infections, and do follow up HIV testing.
* Follow up and monitoring during PrEP
1. All persons receiving PrEP should be seen at 1 month since PrEP initiation and at least every 3 months to assess side effects, adherence, and HIV acquisition risk behaviors.
2. All persons receiving PrEP should be seen at least every 3 months to assess for signs or symptoms of acute infection and repeat HIV testing (HIV Ag/anti HIV Ab combo assay). If acute infection is suspected, HIV RNA testing should be performed.
3. Confirmative HIV testing (western blot assay) and HIV RNA testing should be performed for persons with positive results of screening assay (HIV Ag/anti HIV Ab assay). Resistance testing should be performed for persons with confirmed HIV infection during PrEP.
4. If acute HIV infection is suspected during PrEP, PrEP should be stopped, combination antiretroviral therapy with TDF/FTC+boosted protease inhibitor (darunavir/ritonavir) or TDF/FTC + dolutegravir should be prescribed.
5. All persons receiving PrEP should be seen at least every 3 months to monitor eCrCl.
6. Sexually active persons receiving PrEP should be seen at least every 6 months to conduct tests for sexually transmitted infections (i.e. syphilis, gonorrhea, chlamydia).
7. Assessments of bone health are not routinely recommended before the initiation of PrEP or for the monitoring of persons while taking PrEP. However, assessment for bone health can be considered for any person who has a history of pathologic fractures or who has significant risk factors for osteoporosis mineral density PrEP.
8. All persons receiving PrEP should be seen at least 12 months to evaluate the need to continue PrEP as a component of HIV prevention considering HIV acquisition risk behavior, adherence, and so on.
5. Measurement Baseline data will be collected 1 months before initiation of PrEP, and the date of initiation of PrEP.
All persons receiving PrEP should be seen at 1 month since PrEP initiation and at least every 3 months to assess side effects, adherence, and HIV acquisition risk behaviors. During every visits including screening visit, below measures are assessed.
* Diagnostic testing: HIV testing with a fourth generation HIV Ag/Ab test, HIV RNA assay, serologic test for syphilis using VDRL or RPR, screening for gonorrhoea and chlamydia using nucleic acid amplification test
* Sociodemographics and sexual behaviors: demographic and sexual behavioral data are collected by trained interviewers using standardized questionnaires including residence, living situation, employment, insurance status, income, housing/food instability, drug use, number of anal sex partners, episodes in the past 3 months, condom use, partner HIV serostatus, sexual position, etc.
Study:
NCT04583267
Study Brief:
Protocol Section:
NCT04583267